Hansa Biopharma is a Swedish biopharmaceutical company that develops and commercializes immunomodulatory enzyme therapies for the treatment of rare autoimmune conditions and transplant rejection. The company was founded in 2001 and is headquartered in Lund, Sweden.

Hansa Biopharma's main focus is on the development of therapies that target the immune system to address unmet medical needs in areas such as kidney transplantation, autoimmune disease and antibody-mediated rejection. acute (AMR). Their main product candidate is called imlifidase, formerly known as IdeS. Imlifidase is an enzyme-based treatment designed to selectively cleave antibodies and remove them from the circulation, potentially reducing the risk of rejection in solid organ transplants.

To target pathogenic or pathogenic antibodies, they have created their own patented platform for antibody cleaving enzyme technology. Imlifidase, a first-generation IgG cleavage enzyme, is engineered to inactivate IgG antibodies in tissue and plasma with a single intravenous injection. In transplantation, autoimmunity, gene therapy and cancer, they are actively examining the use of this protein to treat and avoid abnormal diseases caused by IgG antibodies in the acute phase

Founded: 2001

Headquarters: Lund, Sweden

Number of employees: 141

Website: https://www.hansabiopharma.com/

Camurus AB is a Swedish pharmaceutical and biotechnology business focused on the commercialization of drugs for the treatment of serious and chronic diseases . The company was founded in 1991 and has its headquarters in the southern university town of Lund in the Medicon Valley, listed on Nasdaq Stockholm as a Mid Cap company.

Experienced lipid-phase structure scientists from the fields of biochemistry, food and pharmaceuticals have developed Camurus. The business offers advanced drug delivery methods at the nanoscale to create highly effective treatments.

Camurus wants to work with pharmaceutical and biotech companies around the world to enable and enhance the supply of a wide range of medicinal ingredients. These substances, including peptides, proteins, and insoluble small molecules, are delivered using lipid nanocarriers, long-acting depots, and other methods that increase intravenous absorption, through skin and by mouth.

Healthcare needs in the unusual areas of growth hormone, oncology, cancer supportive care, metabolic disease and drug addiction are the goals of Camurus' in-house product range. British investors selected Camurus as the best private biotech company in the Medicon Valley in 2007 after evaluating six nominated private companies. The business received the 2007 Rigorous Finance Award. The CPhI Pharma Award for Best Innovation in Formulation was presented to Camurus in 2013.

Founded: 1991

Number of employees: over 180 employees

Headquarters: Lund, Sweden
Website: https://www.camurus.com/

The Swedish business Genovis AB is involved in the creation, production, and sale of tools and equipment for cellular research. The two product portfolios that the company offers are the protein portfolio and the nano portfolio.

The protein portfolio creates products for autoimmune, inflammatory, and cancerous illnesses. The portfolio includes IgGZERO, a protein that preferentially cleaves the sugar molecules found naturally on antibodies, and FabRICATOR, a genetically modified enzyme that splits antibodies in half. The preclinical market is the target market for the majority of the nano portfolio's goods. Through dealers and distributors throughout the continents of Europe, North America, and Asia, the company markets and sells its goods. It ran Eijdo Research AB, a fully owned subsidiary, as of December 31, 2011.

Scientists from all around the world employ Genovis enzyme products, also known as SmartEnzymes, and the cutting-edge product formats simplify the creation and quality assurance of biological therapies. Genovis AB is one of the largest biotech companies in Sweden is BioInvent.

Founded: 1999

Number of employees: over 20 employees

Headquarters: Lund, Sweden

Website: https://www.genovis.com/

BioArctic is a biopharmaceutical company focused on research. In order to advance significant ground-breaking discoveries made by Professor Lars Lannfelt on Alzheimer's disease, the company was established in 2003 by Dr. Pär Gellerfors and Professor Lars Lannfelt. These discoveries—the Swedish mutation and the Arctic mutation—have garnered significant international attention and shed light on the crucial function that amyloid-beta plays in Alzheimer's disease. As a result, novel therapeutic approaches have been created.

When the company's first medication candidate antibody, BAN2401 for Alzheimer's disease, was developed, BioArctic created a patented technology platform that proved successful. A biotech business called SynAct Pharma seeks to reduce inflammation by utilizing melanocortin biology. Phase 2 rheumatoid arthritis drug development is underway for their lead asset, AP1189. A once-daily tablet form of the immunomodulatory small molecule AP1189 is available.

With the completion of the purchase of TXP Pharma AG in January 2023, SynAct greatly increased the scope of its melanocortin technology portfolio by adding complementary peptide agonists that could be tailored to a variety of autoimmune and inflammatory disorders. This is one of the largest biotech companies in SS

Founded: 2003

Number of employees: 28 employees

Headquarters: Stockholm, Stockholms Lan, Sweden

Website: https://synactpharma.com/en/

Oncopeptides, a Stockholm-based company founded in 2000, specializes in creating medications for the treatment of cancer. The creators of Oncopeptides include some of Sweden's top oncology, clinical, and medical researchers, many of whom have achieved international recognition in their professions.

Melflufen, the first peptidase-potentiated cytotoxic medication designed for use in the treatment of multiple myeloma, was created by Oncopeptides. Oncopeptides has collaborated with eminent scientists and organizations in Europe and the US, such as the Dana Farber Cancer Institute of Harvard Medical School. Data from two phase I/II studies of its medication, melflufen, were presented by researchers in June 2019 at the European Haematology Association in Amsterdam. In 2017, Oncopeptides were listed on the Nasdaq Stockholm.

For difficult-to-treat hemophilia illnesses, Oncopeptides is creating novel therapeutic candidates. The development is based on their Peptide Drug Conjugate (PDC) and Small Polypeptide-based Killer Engagers (SPiKE) technologies and enables us to grow into new indications and build a strong pipeline.

Founded: 2000

Number of employees: 76 employees

Headquarters: Stockholm, Sweden

Website: https://www.oncopeptides.com/en

Orexo was established in Uppsala, Sweden, in 1995 with the goal of improving pharmaceutical goods to address unmet patient requirements. In 2000, the business registered Diabact® UBT, a breath test for detecting the stomach ulcer-causing bacterium Helicobacter pylori. From an R&D stage firm to a viable pharmaceutical company with commercial operations in the US, Orexo has evolved.

The business wants to lead the way in the treatment of opioid addiction. The American market for buprenorphine/naloxone medicines and the commercialization of Zubsolv®, a medication that is successful in treating opioid addiction, are Orexo's main markets. According to CEO Nikolaj Srensen, "Three of their four internal pipeline projects are ready to progress into the next development phase, their financial position continues to strengthen due to sales growth, and their manufacturing efficiency program has had a significantly positive impact on the gross profit contribution from Zubsolv." These factors all point to a bright future for the company in 2019. Orexo was enlisted on the Nasdaq Stockholm in 2005.

Founded: 1995

Number of employees: 123 employees

Headquarters: Uppsala, Sweden
Website: https://orexo.com/

Immunicum is a clinical-stage immuno-oncology business established in Stockholm in 2002 with a primary goal of creating allogeneic dendritic cell technology. Based on research initially conducted at Sahlgrenska University Hospital in Gothenburg. Immunicum works to strengthen a patient's immune system so it can combat cancer, which improves survival rates and quality of life. Ilixadencel, the company's flagship product, is made up of allogeneic pro-inflammatory dendritic cells.

Immunicum anticipates the Phase II MERECA kidney cancer study results in 2019, marking a significant clinical advancement for the drug ilixadencel and the business. There are 88 patients in all in both Europe and the US for this company's first comparative trial. According to CEO de Sousa, "we see a potential for ilixadencel to become a backbone therapy in several future immunotherapies" because it "can be produced and stored for extended periods, and their data indicates that it might enhance the effect of different classes of I/O-drugs, like checkpoint inhibitors, immune enhancers, and other targeted therapies." In 2013, Immunicum debuted on the Nasdaq Stockholm.

Founded: 2002

Headquarters: Stockholm, Sweden

Website: https://mendus.com/

One of the largest biotech companies in Sweden is BioInvent. Human antibody libraries made by BioInvent, a biotechnology research and development business founded in 1997, can be used in a variety of different applications. BioInvent provides proteins to pharmaceutical and biotechnology firms, issues licences for the use of its libraries, and forms alliances to research and produce protein-based medicines.

The primary goal of BioInvent is the identification and development of immuno-modulatory antibodies for the treatment of cancer. It advances this goal through partnerships with major pharmaceutical firms, academic research centres, clinical specialist networks, and research foundations. Three products are now in the clinical stages at BioInvent. Its primary programme, BI-1206, is a treatment with a substantial economic prospect and is currently in Phase l/lla for non-Hodgkin lymphoma and chronic lymphatic leukaemia. THR-317, which Oxurion is now developing for diabetic macular edoema, and TB-403, which was developed in conjunction with Oncurious for juvenile brain tumours, are further drugs in the clinical pipeline. The preclinical pipeline of BioInvent includes a partnership with Pfizer to create antibodies that target regulatory T cells as well as myeloid cells linked to tumours.

Founded: 1997
Headquarters: Lund, Sweden
Website: https://www.bioinvent.com/en